TGA offers first clues to where industry can expect to face regulatory reform

The Therapeutic Goods Administration (TGA) has given the industry an indication of the areas where it can expect to see regulatory reform after publishing a summary of the submissions received during its two-month consultation.

The regulator said 790 submissions were lodged from a range of individuals and organisations with “agreement across stakeholder groups” that the current system for accessing medicinal cannabis was not fit-for-purpose and “not proportionate to the potential safety and quality risks associated with unapproved medicinal cannabis products”.